SCM
CYT

Suvretta Capital Management’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Suvretta Capital Management’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-175,000
Closed -$3.75M – 135
2021
Q2 		$3.75M Buy
+175,000
New +$3.28M 0.06% 96

Other funds holding CYT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Suvretta Capital Management's CYT Position: Q3 2021 in Review

Suvretta Capital Management sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q3 2021, closing a stake of 175,000 shares — an estimated $3.75M sold.

Suvretta Capital Management first reported a position in CYT in Q2 2021 and held it in 1 quarter. The position peaked at $3.75M in Q2 2021. 38 funds tracked by Wall St. Rank hold CYT as of Q3 2021.

  • Suvretta Capital Management reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Suvretta Capital Management sold 175,000 Cyteir Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $3.75M.
  • Suvretta Capital Management first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Suvretta Capital Management's Cyteir Therapeutics, Inc. Common Stock position peaked at $3.75M in Q2 2021.
  • 38 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Suvretta Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.